Market Cap (In USD)
2.23 Million
Revenue (In USD)
-
Net Income (In USD)
-6.59 Million
Avg. Volume
552.46 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.61-4.944
- PE
- -
- EPS
- -
- Beta Value
- 0.74
- ISIN
- US8256932034
- CUSIP
- 825693203
- CIK
- 1757499
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Anatoly Dritschilo M.D.
- Employee Count
- -
- Website
- https://www.shuttlepharma.com
- Ipo Date
- 2022-08-31
- Details
- Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
More Stocks
-
0KODPrologis, Inc.
0KOD
-
EKGYO
-
0RKL
-
1340
-
KUBTFKubota Corporation
KUBTF
-
GODN
-
G6M
-
ACCONAcconeer AB (publ)
ACCON